In contrast to the intensifying supply and demand difficulties of cold medicine and the decline in the performance of respiratory Rx drugs such as antibiotics and expectorants. After the transition to COVID-19 home treatment, the shortage phenomenon intensified, and the pharmaceutical industry began to "excess production." Demand for OTC cold medicines is soaring due to the spread of Omicron mutations. Some pharmaceutical companies have begun overproduction to expand supply.

This is in contrast to the prolonged slump in Rx drugs such as antibiotics and expectorants used in respiratory infectious diseases. The Corona crisis is acting as a boom in the OTC market and a recession in the Rx drug market.